Physicians are turning to other options, including older, cheaper medications, as compounding GLP-1s comes to an end.

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that patients using GLP-1 or combined GLP-1 / GIP receptor agonist therapy for ...

LongeVC, an international investor based in Latvia, has injected an unspecified sum into Cambridge company Constructive Bio ...

A WOMAN felt -like she was being “ripped open by a knife” after suffering extreme reaction to a single weight loss jab. Karen Coe, 59, decided to try the injections to lose weight and help combat ...

About half of Americans "strongly" or "somewhat" favor having Medicare and Medicaid cover weight-loss drugs for people who ...

In the ever-evolving landscape of healthcare, telemedicine has emerged as a transformative force, providing individuals with ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Senator John Fetterman, a democrat from Pennsylvania, admitted to using weight loss drug Mounjaro and issued a desperate plea ...

A MOTHER has revealed that she lost over seven stone after using Ozempic for 12 months. Hannah, who is from the United States ...

Explore the impact of proposed Pharma tariffs on global markets as major stocks tumble. Click for my updated look at selected picks in the health industry.

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability issue of obesity medications such as Wegovy and Zepbound.